Magnevist (gadopentetate dimeglumine) is one of the eight gadolinium-based MRI contrast dye agents approved by the U.S. Food & Drug Administration (FDA), to enhance MRI scan results. It has been linked to reports of a painful and debilitating condition known as Gadolinium Deposition Disease.
According to a recent lawsuit filed in the U.S. District Court for the Northern District of California on May 13, a plaintiff alleged exposure to Magnevist during an MRI exam caused brain fog, joint pain, and skin problems which are the symptoms of Gadolinium Deposition Disease (GDD). Further allegations faced by defendants Bayer Corporation and McKesson Corporation include failure to warn, negligence, design defect, misrepresentation, breach of warranty, negligent misrepresentation, fraudulent misrepresentation, and consumer protection violations.
The lawsuits against MRI gadolinium are increasing in numbers in recent months, each raising similar allegations over its side effects. Gadolinium related lawsuits are centralized under MDL No. 1909; In Re: Gadolinium Contrast Dyes Products Liability Litigation.
